September 2019 Issue of The Medicine Maker

Should pharma companies transition from developing, manufacturing and pricing “drugs” to promoting “health”?

A new vaccine could help give people at risk of HIV more options.

"Let's adopt a lifecycle management approach to method development to ensure continued excellence."

Clinical trials need an overhaul – and AI is the solution.

Before you start building a new ATMP facility, there is one essential element that you need to get right: site selection.

Male animal bias in preclinical research isn’t scientifically justified and may be skewing our understanding of the brain.

Researchers at the University of Bath have developed a technique which could prevent drugs from spoiling.

Sue Springett, Commercial Manager at Teknomek, explains the importance of health and safety in a solid coroporate social responsibility strategy.

Tablet coating is not just about aesthetics; a good coat will improve stability, aid patient adherence, and enhance manufacturing productivity.

There could be significant benefits to implementing additional measures in upstream bioprocesses to prevent viral contamination.

Combine standardized, single-use platform technologies that can be customized to your particular process requirements, for crucial efficiency gains.

The Jefferson Institute for Bioprocessing is up and running after just two years. How did they do it? And what courses are on offer?

Maeve Magner explains how digital solutions can improve the supply chains of emerging economies.

Sitting Down With… Joan Mannick, Co-Founder and Chief Medical Officer at resTORbio, Massachusetts, USA.